Cardiovascular mortality in chronic renal failure: hyperphosphatemia, coronary calcification, and the role of phosphate binders.
Fatica
Richard A
RA
Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, OH 44195, USA. faticar@ccf.org
Dennis
Vincent W
VW
D000085:Acetates / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D002114:Calcinosis / Q000209:etiology*; D002118:Calcium / Q000378:metabolism*; D017610:Calcium Compounds; D003324:Coronary Artery Disease / Q000209:etiology / Q000401:mortality* / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D010710:Phosphates / Q000097:blood*; D011073:Polyamines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis; D012307:Risk Factors
D000085:Acetates; D000863:Antacids; D017610:Calcium Compounds; D010710:Phosphates; D011073:Polyamines; C063994:polyallylamine; D002118:Calcium; C120662:calcium acetate